- Home
- TARA vs IMRX Comparison
TARA vs IMRX Comparison
Compare TARA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- IMRX
- Stock Information
- Founded
- TARA N/A
- IMRX 2008
- Country
- TARA United States
- IMRX United States
- Employees
- TARA N/A
- IMRX N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- IMRX Health Care
- Exchange
- TARA Nasdaq
- IMRX Nasdaq
- Market Cap
- TARA 126.5M
- IMRX 145.7M
- IPO Year
- TARA N/A
- IMRX 2021
- Fundamental
- Price
- TARA $3.33
- IMRX $4.06
- Analyst Decision
- TARA Strong Buy
- IMRX Strong Buy
- Analyst Count
- TARA 7
- IMRX 4
- Target Price
- TARA $20.67
- IMRX $13.25
- AVG Volume (30 Days)
- TARA 450.2K
- IMRX 922.9K
- Earning Date
- TARA 08-05-2025
- IMRX 08-05-2025
- Dividend Yield
- TARA N/A
- IMRX N/A
- EPS Growth
- TARA N/A
- IMRX N/A
- EPS
- TARA N/A
- IMRX N/A
- Revenue
- TARA N/A
- IMRX N/A
- Revenue This Year
- TARA N/A
- IMRX N/A
- Revenue Next Year
- TARA N/A
- IMRX N/A
- P/E Ratio
- TARA N/A
- IMRX N/A
- Revenue Growth
- TARA N/A
- IMRX N/A
- 52 Week Low
- TARA $1.60
- IMRX $1.00
- 52 Week High
- TARA $10.48
- IMRX $4.69
- Technical
- Relative Strength Index (RSI)
- TARA 55.94
- IMRX 59.69
- Support Level
- TARA $3.25
- IMRX $3.95
- Resistance Level
- TARA $3.23
- IMRX $4.69
- Average True Range (ATR)
- TARA 0.17
- IMRX 0.36
- MACD
- TARA 0.04
- IMRX -0.09
- Stochastic Oscillator
- TARA 81.25
- IMRX 27.62
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.